Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.